October 19, 2009 15:03 ET

Developer Says CEL-SCI's L.E.A.P.S. Technology Has Extensive Applications

LOS ANGELES, CA--(Marketwire - October 19, 2009) -, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, in an exclusive interview with Daniel H. Zimmerman, Ph.D., of CEL-SCI Corporation, (NYSE Amex: CVM) is reporting that treatments and applications for the company's L.E.A.P.S platform technology may reach far beyond rheumatoid arthritis and H1N1.

This past weekend, new rheumatoid arthritis data presented at the American College of Rheumatology's annual meeting in Philadelphia by Dr. Zimmerman, indicates that CEL-2000, a vaccine based upon the company's L.E.A.P.S. technology, acts to prevent or retard the permanent tissue damage caused by rheumatoid arthritis, but the statistically significant results may only be part of the scientific journey for technology.

"I've been working on this technology for over twenty years," explains Zimmerman, "We've stuck with it since 1987, firmly believing in it, being the key developer for it. Things are finally starting to take off. We're seeing now that the applications are as extensive as we thought that they would be originally in the areas of infectious diseases, autoimmune, perhaps even cancer and other types of conditions, but we've been limited in our resources so we had to concentrate on some key areas, hence the rheumatoid arthritis results."

The complete special report is available now at

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Contact:
    M. Davila
    +1 323-472-4480
    Fax: +1 888-210-3556
    Email Contact